» Articles » PMID: 10648020

Hemostatic Factors and Cardiovascular Disease in Active Rheumatoid Arthritis: an 8 Year Followup Study

Overview
Journal J Rheumatol
Specialty Rheumatology
Date 2000 Jan 27
PMID 10648020
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To investigate the prospective effect of hemostatic factors and inflammatory variables on the progression of cardiovascular disease in rheumatoid arthritis (RA).

Methods: Von Willebrand factor (vWF) and the fibrinolytic factors tissue plasminogen activator (tPA), measured as tPA capacity, and plasminogen activator inhibitor 1 (PAI-1), platelets, fibrinogen, and inflammatory markers were measured in 74 patients with active seropositive RA. Lipid levels, lipoprotein(a), and cardiolipin antibodies were also analyzed. Cardiovascular disease, measured by past cardiovascular events including thrombotic events, was registered in an 8 year followup.

Results: Patients with a cardiovascular event during the followup period (n = 26) had significantly higher levels of vWF, PAI-1, erythrocyte sedimentation rate (ESR), and haptoglobin at entry to the study. In a multiple logistic regression model controlling for several conventional cardiovascular risk factors and pharmacological treatment at sampling, PAI-1 and tPA were significantly associated with cardiovascular disease progression.

Conclusion: The altered levels of vWF, PAI-1, and, in logistic regression, tPA in RA patients with cardiovascular disease progression indicates a status of hypofibrinolysis in these patients. Higher levels of ESR and haptoglobin may reflect the importance of the inflammatory process for the development of cardiovascular disease in RA.

Citing Articles

A comparative study on serum lipoprotein (a) and lipid profile between rheumatoid arthritis patients and normal subjects.

Govindan K, Basha S, Ramesh V, Kumar C, Swathi S J Pharm Bioallied Sci. 2015; 7(Suppl 1):S22-5.

PMID: 26015716 PMC: 4439676. DOI: 10.4103/0975-7406.155767.


Novel risk factors for cardiovascular disease in rheumatoid arthritis.

Amaya-Amaya J, Sarmiento-Monroy J, Mantilla R, Pineda-Tamayo R, Rojas-Villarraga A, Anaya J Immunol Res. 2013; 56(2-3):267-86.

PMID: 23584985 DOI: 10.1007/s12026-013-8398-7.


Carotid enlargement and serum levels of von Willebrand factor in rheumatoid arthritis: a follow-up study.

Veselinovic M, Jakovljevic V, Jurisic-Skevin A, Toncev S, Djuric D Clin Rheumatol. 2012; 31(12):1727-32.

PMID: 22960771 DOI: 10.1007/s10067-012-2079-0.


Protective effect of methotrexate in patients with rheumatoid arthritis and cardiovascular comorbidity.

Marks J, Edwards C Ther Adv Musculoskelet Dis. 2012; 4(3):149-57.

PMID: 22850632 PMC: 3400102. DOI: 10.1177/1759720X11436239.


Lack of association between polymorphisms of thrombogenic genes and disease susceptibility in rheumatoid arthritis.

Dimitroulas T, Douglas K, Smith J, Panoulas V, Kitas G Rheumatol Int. 2012; 33(9):2429-32.

PMID: 22466403 DOI: 10.1007/s00296-012-2392-6.